
PRESS RELEASE

<u>BSE: 506690</u>	<u>NSE: UNICHEMLAB</u>	<u>Reuters: UNLB.BO</u>	<u>Bloomberg: UN@IN</u>
---------------------------	-------------------------------	--------------------------------	--------------------------------

Mumbai, October 7, 2011

Unichem Laboratories receives ANDA approval from USFDA for LAMOTRIGINE TABLETS

Unichem Laboratories Limited is pleased to announce that it has received ANDA approval from the United States Food and Drug Administration (U.S. FDA) for Lamotrigine Tablets.

Lamotrigine Tablets USP 25mg, 100mg, 150mg and 200mg are therapeutically equivalent to LAMICTAL® Tablets USP 25mg, 100mg, 150mg and 200mg from GlaxoSmithKline.

Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and for maintenance treatment of bipolar disorder.

The product will be commercialized from Unichem's Goa plant. Active pharmaceutical ingredient i.e. Lamotrigine used for this ANDA is also made in house at Pithampur plant. This ANDA approval will enhance the presence of Unichem in US market. Unichem already has 10 other ANDA's duly approved and there are some more ANDA's in pipeline.

About Unichem Laboratories Limited.

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms.

More information about the company can be found at www.unichemlabs.com.

Contacts:

Mr. K Subharaman

Mr. Rakesh Parikh

Mr. M Gundu Rao

Tel: +912266888404

Tel: +912266888414

Tel: +912266888380

Cell: +919833031121

Cell: +919892925555

Cell: +919820228944

e-Mail: subharamank@unichemlabs.com rparikh@unichemlabs.com gundurao@unichemlabs.com



This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
